PeptiDream与PDRadiopharma将在EANM'26发布64Cu-PD-29875与225Ac-PD-29875临床前结果

News Release

October 9, 2026

PeptiDream Inc
https://www.peptidream.com
(Securities Code: 4587 TSE Prime Market)
PDRadiopharma Inc
https://www.pdradiopharma.com/

Upcoming Conference Presentation for Radiopharmaceutical
Program at EANM’26

KAWASAKI, JAPAN – October 9, 2026 - PeptiDream Inc., a public biopharmaceutical
company based in Kawasaki, Japan, focused on the discovery and development of peptide-
based therapeutics (Representative Director & CEO: Patrick C. Reid), today announced that
PeptiDream and PDRadiopharma Inc. (President: Masato Murakami; Headquarters: Chuo-ku,
Tokyo, Japan), a wholly owned subsidiary of PeptiDream, will present preclinical results from
their joint research efforts on PeptiDeam’s in-houose theranostics program, 64Cu-PD-29875
and 225Ac-PD-29875, at the Annual Congress of the European Association of Nuclear
Medicine (EANM’26) held in Vienna, Austria from October 17-21, 2026.

Information on the presentation is as follows;

Annual Congress of the European Association of Nuclear Medicine (EANM’26)
(October 17-21, 2026)
Location: Vienna, Austria

Title: First-in-class Claudin 18.2 targeting radiopeptide, 64Cu-PD-29875 and 225Ac-PD-
29875, exhibit promising theranostic potential in pancreatic and gastric cancer xenograft
models
Presentation Format: e-Poster (EP-0157)
Date: October 17-21, 2026

About PD- 29875
PD-29875 is a macrocyclic peptide targeting Claudin 18.2 (CLDN18.2) discovered using
PeptiDream’s proprietary PDPS® technology and further optimized through in vivo imaging
and efficacy studies conducted at PDRadiopharma. CLDN18.2 is highly expressed in a variety
of solid tumors, including gastric cancer, esophageal cancer, pancreatic cancer and lung
adenocarcinoma. It has been reported to regarded as an attractive molecular target for both
cancer diagnosis and therapy. PD-29875 is being developed as a theranostic platform through
labeling with the diagnostic radionuclide 64Cu and the therapeutic radionuclide 225Ac. a Phase
0 clinical study of 64Cu-PD-29875 is currently underway in patients with gastric cancer and
GEJ cancer to evaluate its safety, pharmacokinetics, and tumor uptake. The program was
adopted by Japan Agency for Medical Research and Development (AMED) as part of the
“Practical Research for Innovative Cancer Control” and received funding support from AMED
in 2024.

About PeptiDream Inc.
PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic
peptides into a whole new class of innovative medicines to address unmet medical needs and improve
the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned
subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved
radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide
Discovery Platform System (PDPS®) technology to discover and develop a deep pipeline of innovative
targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and
globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly
leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide
therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an
extensive global network of discovery and development partners. PeptiDream is headquartered in
Kawasaki, Japan. For more information about our company, science and pipeline, please visit
www.peptidream.com/en/

About PDRadiopharma
PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality
radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as
a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently
PDRadiopharma offers 21 radiodiagnostic products (spanning both SPECT and PET products) and 8
radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and
PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the
Japan and global markets. For more information about PDRadiopharma, please visit
https://www.pdradiopharma.com/en/

Inquiries:

PeptiDream Inc.
Contact: Yuko Okimoto, IR & Corporate Communications
Email: [email protected]
Website: https://www.peptidream.com/en/
X: https://x.com/PeptidreamInc
LinkedIn: https://www.linkedin.com/company/peptidream

PDRadiopharma Inc.
Contact: Noriko Tanaka, General Affairs
Email: [email protected]
Website: https://www.pdradiopharma.com/en/
X: https://x.com/PDRadiopharma
LinkedIn: https://www.linkedin.com/company/pdradiopharma-inc